Cryo-Cell International (NYSEAMERICAN:CCEL) Shares Cross Below 200-Day Moving Average – Time to Sell?

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL)’s stock price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $3.46 and traded as low as $3.13. Cryo-Cell International shares last traded at $3.88, with a volume of 681,766 shares.

Cryo-Cell International Price Performance

The business’s 50 day simple moving average is $3.53 and its 200 day simple moving average is $3.46. The stock has a market cap of $31.92 million, a P/E ratio of -13.20 and a beta of 0.48.

Cryo-Cell International (NYSEAMERICAN:CCEL) last released its quarterly earnings data on Wednesday, July 15th. The company reported $0.07 earnings per share for the quarter. The company had revenue of $7.78 million during the quarter.

Institutional Trading of Cryo-Cell International

A hedge fund recently bought a new stake in Cryo-Cell International stock. Susquehanna International Group LLP acquired a new position in shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned approximately 0.14% of Cryo-Cell International at the end of the most recent reporting period. 10.44% of the stock is owned by hedge funds and other institutional investors.

About Cryo-Cell International

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.